Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On March 18, 2023, Yvonne Greenstreet notified the Board of Directors (the "Board") of Pacira BioSciences, Inc. (the "Company") of her intent to of her intent to retire from the Board, effective March 31, 2023. Dr. Greenstreet is currently serving as Chief Executive Officer of Alnylam Pharmaceuticals, Inc., a Nasdaq-listed public company. Pacira is initiating a process to identify an independent Board member to replace Dr. Greenstreet. Dr. Greenstreet's decision to retire was not a result of any disagreement with the Company on any matter relating to the Company's operations, policies, or practices.

Item 7.01. Regulation FD Disclosure.

On March 22, 2023, the Company issued a press release related to Dr. Greenstreet's resignation from the Board and to thank her for service. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 7.01 and Exhibit 99.1 furnished hereto shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.



(d) Exhibits

       Exhibit                               Description
       Number

        99.1          Press Release dated March 22, 2023.

         104        Cover Page Interactive Data File (Formatted as Inline XBRL)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses